Who
Scott Dunseth Myers
Director
Company insider
Files Form 4 as: Director, Zentalis Pharmaceuticals; Director, Dynavax Technologies; Director, Harpoon Therapeutics; Director, Cartesian Therapeutics; Chief Executive Officer, Viridian Therapeutics; Director, Trillium Therapeutics; President & CEO, Amag Pharmaceuticals; President and CEO, Cascadian Therapeutics.
In numbers
- Trades disclosed
- 94
- Buys
- 13
- Sells
- 0
- Bought
- $582K
- Sold
- $0
- Companies
- 9
- Companies where not an officer
- 5
- First trade
- 24 May 2006
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,100 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,100 at $0.00 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax TechnologiesBiotechnology | SEC FORM 4 Code U | —3,800 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax TechnologiesBiotechnology | SEC FORM 4 Code D | —31,204 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —45,000 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —16,875 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —22,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —22,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code D | —28,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,875 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code D | —28,500 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologies | SEC FORM 4 Code U | —3,800 | filing |
| 10 Feb 2026filed 10 Feb 2026 | Dynavax Technologies | SEC FORM 4 Code D | —31,204 | filing |
| 22 Aug 2025filed 25 Aug 2025 | Dynavax Technologies | SEC FORM 4 Bought | $41K3,800 at $10.82 | filing |
| 17 Jun 2025filed 18 Jun 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,603 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code A | —28,500 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | Dynavax Technologies | SEC FORM 4 Code A | —5,758 at $0.00 | filing |
News
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 7.8% – Here's WhyVRDN · dailypolitical.com · 19 Oct 2026Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractZNTL · manilatimes.net · 18 Oct 2026Critical Survey: Emergent Biosolutions (NYSE:EBS) & Viridian Therapeutics (NASDAQ:VRDN)VRDN · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Scott Dunseth Myers; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.